ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00866762
Recruitment Status : Unknown
Verified December 2011 by Copenhagen University Hospital at Herlev.
Recruitment status was:  Active, not recruiting
First Posted : March 20, 2009
Last Update Posted : December 12, 2011
Sponsor:
Information provided by (Responsible Party):
Copenhagen University Hospital at Herlev

March 17, 2009
March 20, 2009
December 12, 2011
February 2009
August 2012   (Final data collection date for primary outcome measure)
To evaluate the efficacy of study drug (MK-0683) in the treatment of patients with PV and ET. [ Time Frame: one year ]
Same as current
Complete list of historical versions of study NCT00866762 on ClinicalTrials.gov Archive Site
To study changes in bone marrow morphology before and after treatment with study drug. [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
 
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia.
The aim of the present study is to evaluate the efficacy and safety of MK-0683 in the treatment of PV and ET. This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic cells of PV and ET patients carrying the JAK2 V617F mutation. Accordingly, it may be anticipated that MK-0683 - by decreasing the JAK2 allele burden - may influence clonal myeloproliferation and in vivo granulocyte, platelet and endothelial activation , which are considered to be major determinants of morbidity and mortality ( thrombosis, bleeding, extramedullary haematopoiesis , myelofibrosis ) in these disorders. The effects of MK-0683 at the molecular level will be studied by global/ focused gene expression profiling, epigenome profiling and proteomics.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Polycythemia Vera
  • Essential Thrombocythemia
Drug: HDAC inhibitor (MK-0683)
400 mg once daily for 6 months
Experimental: 1
Treatment with study drug approximately 6 months and follow-up for 3 months
Intervention: Drug: HDAC inhibitor (MK-0683)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
60
Same as current
December 2012
August 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patient > 18 years of age AND
  • A confirmed diagnosis of PV AND
  • Biochemical evidence of active disease as defined by:

    • a need for phlebotomy within last 3 months
    • a leukocyte count > 10 x 10^9/L in the absence of infection or inflammation (normal CRP) and/or (PV/ET)
    • a platelet count > 450 x 10^9/L in the absence of infection or inflammation (normal CRP)(PV/ET) OR
  • Male or female patient > 18 years of age AND
  • A confirmed diagnosis of ET AND
  • Biochemical evidence of active disease as defined by *a platelet count > 450 x 10^9/L in the absence of infection or inflammation

Inclusion Criteria for both PV and ET:

  • Newly diagnosed or previously treated patient in chronic phase OR
  • Advanced phase PV or ET as defined by blasts of > 1 x 10^9/L in the peripheral blood and/or white cell count > 30 x 10^9/L OR
  • Resistant or refractory PV or ET as defined by haemoglobin < 10.5 gm/dl with a platelet count > 600 x 10^9/L on current therapy OR
  • Cycling platelet counts on therapy OR
  • Intolerant to other therapies defined by patients with PV or ET who have side effects on current therapies preventing continuation (leg ulcers on hydroxycarbamide, unacceptable fatigue etc on interferon)

Exclusion Criteria:

  • A platelet count > 1500 x 10^9/L (a need for cytoreduction in platelet count)
  • Patients of childbearing potential without a negative pregnancy test prior to initiation of study drug
  • Women who are breast feeding
  • Males and females not using contraceptives if sexually active.
  • EGOC Performance status Score > or = 3
  • Serum creatinine more than 2 x's teh ULN
  • Total serum bilirubin more than 1.5 x's the ULN
  • Serum AST/ALT more than 3 x's the ULN
  • Interferon alpha within 1 week of day 1
  • Hydroxycarbamide within 1 week of day 1
  • Anagrelide within 1 week of day 1
  • Valproic acid (as an anticonvulsant) within 28 days of day 1
  • Any other investigational drug within 28 days of day 1
  • Active HIV, HBV or HCV infection
  • Any serious concomitant disease or circumstances that could limit compliance with the study, including but not limited to the following: CTCAE grade 3-4 cardiac general & arrhythmia, or psychiatric or social conditions that may interfere with patient compliance.
  • Any prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed to be at low risk for recurrence by his/her treating physician.
  • Patient has a known allergy or hypersensitivity to study drug.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Denmark,   Netherlands,   Sweden,   United Kingdom
Belgium
 
NCT00866762
MK-0683/092-0
Yes
Not Provided
Not Provided
Copenhagen University Hospital at Herlev
Copenhagen University Hospital at Herlev
Not Provided
Principal Investigator: Hans C Hasselbalch, MD Department of Hematology, Copenhagen University Hospital Herlev
Copenhagen University Hospital at Herlev
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP